TP53 and myeloproliferative disorder: According to WHO2022 and ICC2022 classifications, the diagnosis of AML with defining genetic abnormalities was found in 40 (53.3%) cases, AML with myelodysplastic syndrome gene mutations (AML MDS-related) in 12 (16%) cases, AML defined by differentiation in 8 (11%) cases, AML secondary to previous myeloproliferative neoplasms (AML post-MPN) in 7 (9.3%) cases, therapy-related AML in 3 (4%) cases, and finally, MDS/AML with a TP53 mutation in 5 (6.7%) cases.